Alpha-lipoic acid with benfotiamine for nerve damage symptoms in diabetes
Tests alpha-lipoic acid plus benfotiamine for symptoms of diabetic sensorimotor polyneuropathy in adults.
Key facts
- Who runs it
- Woerwag Pharma GmbH & Co. KG
- Where
- Hungary10 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Efficacy and safety of a combined therapy in the symptomatic treatment of diabetic sensorimotor polyneuropathy - a prospective, randomized, controlled, parallel group, double-blind, double-dummy 3-arm trial (ARIEL)
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 136 people, planned
- Started
- 1 Mar 2026
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional
- Record updated
- 24 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 1 or type 2 diabetes who have mild to moderate nerve damage in the legs and feet with symptoms (diabetic sensorimotor polyneuropathy). It tests Alpha-Lipoic Acid and Benfotiamine together for 16 weeks.
- Age
- 18 years and older
- Sex
- Men and women
- Disease stage
- Mild to moderate symptomatic DSPN: abnormal or absent sural nerve test results, NTSS-6 >6 and NDS of 3-8. Diabetes diagnosed at least 1 year before screening. Nerve symptoms for at least 3 months. Stable diabetes with no severe sugar crises in the last 3 months.
- Earlier treatment
- Diabetes medicines or insulin dose must be stable for the last 3 months. SGLT-2 inhibitors must have started at least 26 weeks before screening. No GLP-RA in the last 12 months. No chronic pain medicines in the last 2 months, except stable gabapentin, pregabalin or duloxetine within set limits. No ALA, BEN B-vitamins or similar supplements for 5 days or longer in the last 2 months.
- Biomarker or test result
- HbA1c ≤9.5 % (80 mmol/mol)
Main reasons for not taking part
- Nerve damage from a cause other than diabetes, or other nerve or muscle diseases
- Pregnant or breastfeeding women, or women who can get pregnant and do not use effective birth control
- Serious liver disease (AST or ALT ≥3 times upper limit of normal) or kidney disease (eGFR <30 ml/min/1.73m2)
- Heart attack, stroke or active cancer in the last 12 months, or uncontrolled high blood pressure
- Alcohol or drug abuse, or highest nerve pain score above 9 in the last 4 weeks
The registry criteria, word for word
Show all 37 criteriaShow less
Who can take part
- Written informed consent signed by the participants prior to any performance of trial-related screening procedures
- Diagnosed mild to moderate symptomatic DSPN defined by abnormal or non-evocable sural nerve conduction velocity and/or abnormal or non-evocable sural nerve action potential AND DSPN symptoms (signified by NTSS-6 >6) AND neuropathic signs (signified by NDS of 3-8)
- HbA1c ≤9.5 % at screening or at a time point between screening and randomization
- Willingness to avoid lifestyle changes or changes of diet during the trial (including start of drugs supporting weight loss)
- Participants must have completed and documented their baseline symptom assessment over seven consecutive days and the NTSS-6 questionnaire on the final day of symptom assessment, using the provided ePRO link, in accordance with the protocol-defined schedule within the seven days prior to the randomization visit
- Ability to follow trial restrictions
- Ability to attend scheduled visits at the Investigator site for the duration of the trial
- Existence of a possibility to receive SMS
- Male or female participants ≥18 years old at the time of screening
- Diagnosed diabetes type 1 or 2 (per American Diabetes Association criteria (ADA Standards of Care in Diabetes 2025)), with diagnosis established at least 1 year prior to screening
- Stable diabetes medication use (or stable insulin dose for insulin-dependent participants) in the last 3 months prior to screening, which is unlikely to be changed during the trial period, as judged by the investigator. In case of therapy with SGLT-2 inhibitors, the start of treatment must additionally be at least 26 weeks prior to screening
- Stable diabetes metabolism, defined as no metabolic decompensation within the last 3 months (severe hypoglycaemia with unconsciousness, hyperosmolar hyperglycemic state, or ketoacidosis) prior to randomisation
- Persistent or recurrent neuropathic symptoms (e.g., numbness, tingling, burning or stabbing pain, hypersensitivity) that have occurred at least within 3 months prior to randomization. These symptoms and their duration can be reported by the participant to the Investigator during anamnesis
Who cannot take part
- Female participants with child-bearing potential not using any of the following effective birth control methods at least 2 months prior to randomization: a) oral contraceptives with a stable regimen; b) depomedroxyprogesterone; c) a double barrier method (either combining physical barrier methods e.g. condoms and diaphragm, or combining a physical barrier with a chemical barrier method, e.g. diaphragm/ condoms with spermicides); d) intrauterine device
- Treatment with glucagon-like peptide-1 receptor agonists (GLP-RA) within the last 12 months prior to randomization
- Any pharmacological treatment of chronic pain within the last 2 months prior to randomization. Exception is monotherapy with gabapentin up to 3000 mg/day, pregabalin up to 450 mg/day, or duloxetine up to 60 mg/day, without dose change within 2 months before randomization. For analgesia, standard doses of salicylates, ibuprofen or phenylacetic acid derivatives are allowed over a period of maximal 7 consecutive days, as well as rescue medication with paracetamol up to 3 g/day. Stable acetylsalicylic acid therapy in low doses for blood thinning purposes is also allowed
- A major cardiovascular event, such as myocardial infarction or stroke, or an acute malignant disease in the 12 months prior to randomization
- Current treatment with antidepressants (except stable duloxetine or selective serotonin reuptake inhibitors)
- Maximum neuropathic pain level > 9 over the previous 4 weeks on a NRS as assessed at screening
- Treatment lasting 5 days or longer with concomitant medication containing ALA, BEN B-vitamins, evening primrose oil, deproteinized hemoderivates of calf blood, or other drugs or supplements with potential influence on trial endpoints (e.g. antioxidants) within the last 2 months prior to randomization
- Treatment with cutaneous electrical nerve stimulation, muscle stimulation, or 8 % capsaicin patch within the last 2 months prior to randomization
- Any contraindication to the use of the trial medication, including known allergy/hypersensitivity
- Uncontrolled hypertension (systolic blood pressure >160 mm Hg, or diastolic blood pressure >100 mm Hg), with or without anti-hypertensive medication
- Severe or unstable depression or severe or unstable other psychiatric diseases with potential influence on trial endpoints, as judged by the Investigator
- Any other existing medical conditions, likely to affect the trial measures, as judged by the Investigator
- Neuropathy of any cause other than diabetes (e.g. vitamin B12 deficiency-, chemotherapy-, toxin-, drug- or autoimmune-induced neuropathies, peripheral neuropathies induced by damages of the spinal cord), myopathy, or other neurological diseases that might interfere with trial endpoints
- Currently active or history of alcohol abuse (defined as a regular intake of more than 24 units of alcohol per week for men and 12 units of alcohol per week for women; one unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)
- Current or history of regular use of recreational drugs (except history of occasional or experimental cannabis use in the past, with no evidence of dependence)
- History of a disease (including cardiovascular, pulmonary, gastrointestinal, hematologic, or endocrine disease, or malignancy) that could potentially cause neuropathic pain or symptoms
- Significant hepatic disease (AST or ALT ≥3 times of upper limit of normal)
- Significant renal disease (eGFR <30 ml/min/1.73m2)
- Magnesium deficiency at screening which cannot be compensated until randomization
- Participation in another interventional clinical trial within 2 months preceding randomization. Participation in registries is allowed
- Living in the same household with another participant of this trial
- Pregnant or nursing women at screening
- Severe chronic pain of origin other than DPN which might interfere with the trial endpoints, based on medical history or physical examination (e.g. fibromyalgia)
- Bilateral lower extremity amputations (above the ankle). Individuals with unilateral lower extremity amputation may be included, provided that the remaining limb allows for reliable assessment of neuropathy-related endpoints and safe participation in study procedures
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To assess whether a 16-week combined treatment provides superior effects on symptoms of diabetic sensorimotor polyneuropathy, compared to both pooled and individual monotherapies, based on a structured analytic strategy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Efficacy and safety of a combined therapy with Alpha-Lipoic Acid and Benfotiamine in the symptomatic treatment of diabetic sensorimotor polyneuropathy - a prospective, randomized, controlled, parallel group, double-blind, double-dummy 3-arm trial
- Plain-language title
- Alpha-lipoic acid with benfotiamine for nerve damage symptoms in diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 24 April 2026